Hubert Metzner

USPTO Granted Patents = 28 (Patent Applications = 13)

CIPO Patents = 7 (Patent Applications = 8)

EPO Patents = 24 (Patent Applications = 24)

Average Co-Inventor Count = 3.1

ph-index = 9

Forward Citations = 235(Granted Patents)

Location History:

Lahntal, DE (2001)
Marburg, DE (2001 - 2023)

Company Filing History:

Csl Behring Lengnau Ag

patents

Years Active: 2001-2023

Loading Chart...

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11814421 - Truncated von Willebrand Factor polypeptides for treating hemophilia (2023-11-14),

2. 11554156 - Pharmaceutical formulations of C1 esterase inhibitor (2023-01-17),

3. 11510968 - Method for improving the stability of purified Factor VIII after reconstitution (2022-11-29),

4. 11479578 - Protein purification and virus inactivation with alkyl glycosides (2022-10-25),

5. 10881717 - Method for improving the stability of purified Factor VIII after reconstitution (2021-01-05),

6. 10688157 - Truncated von Willebrand factor polypeptides for treating hemophilia (2020-06-23),

7. 10537616 - Method for improving the stability of purified factor VIII after reconstitution (2020-01-21),

8. 10238718 - Factor VIII formulation (2019-03-26),

9. 9956269 - Method for improving the stability of purified factor VIII after reconstitution (2018-05-01),

10. 9878017 - Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto (2018-01-30),

11. 9511123 - Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII (2016-12-06),

12. 9394353 - Method for improving the stability of purified factor VIII after reconstitution (2016-07-19),

13. 9393289 - Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII (2016-07-19),

14. 9290561 - Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life (2016-03-22),

15. 8754194 - Modified coagulation factors with prolonged in vivo half-life (2014-06-17),

Title: **Hubert Metzner: Innovator in Hemophilia Treatment**

Introduction

Hubert Metzner is a prominent inventor based in Marburg, Germany, known for his significant contributions to the field of biomedicine. With an impressive portfolio of 28 patents, he has focused on developing innovative solutions for blood coagulation disorders, particularly hemophilia. His commitment to research and development has made a substantial impact on pharmaceutical formulations that enhance patient care.

Latest Patents

Metzner's latest innovations include groundbreaking patents that address critical medical needs. One notable patent is for **truncated von Willebrand Factor polypeptides for treating hemophilia**. This invention involves a polypeptide consisting of a truncated von Willebrand Factor (VWF) combined with a half-life extending moiety, designed for treating blood coagulation disorders. The polypeptide aims to enhance the activity level of endogenous Factor VIII (FVIII) in patients with reduced levels, thereby improving their condition.

Another notable invention is related to **pharmaceutical formulations of C1 esterase inhibitor**. This formulation demonstrates higher stability for prolonged storage and reduces the formation of aggregates of the esterase inhibitor. Such advancements are crucial for treating disorders associated with kinin formation, improving treatment outcomes for patients.

Career Highlights

Throughout his career, Hubert Metzner has been associated with reputable organizations, including CSL Behring GmbH and CSL Limited. His work at these companies has played a pivotal role in advancing therapeutic approaches for various blood disorders. Metzner’s dedication to innovation in medical science showcases his impressive trajectory as an inventor.

Collaborations

In his pursuit of innovation, Metzner has collaborated with notable colleagues, including Stefan Schulte and Thomas Weimer. These partnerships have undoubtedly enriched his research efforts and contributed to the successful development of his patented technologies.

Conclusion

Hubert Metzner continues to be a vital force in the realm of biomedical inventions. His latest patents not only reflect his expertise but also signify a commitment to improving the lives of individuals with blood coagulation disorders. Through his innovative spirit and collaborative efforts, Metzner exemplifies the true essence of a dedicated inventor in the field of healthcare.

This text is generated by artificial intelligence and may not be accurate.